Document Detail


Hormone replacement therapy causes a decrease in hepatocyte growth factor in hypertensive women.
MedLine Citation:
PMID:  12777952     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Serum hepatocyte growth factor (HGF) is associated with blood pressure. We investigated whether the serum HGF level differs between hypertensive and normotensive postmenopausal women (PMW) and whether hormone replacement therapy (HRT) alters the serum HGF level and blood pressure in hypertensive and normotensive PMW. DESIGN: Prospective observational study. METHODS: A total of 33 PMW with mild to moderate essential hypertension controlled by antihypertensive treatment (mean age, 57 +/- 6 years) and 23 normotensive PMW (mean age, 57 +/- 7 years) received continuous HRT (0.625 mg of conjugated equine estrogen combined with 2.5 mg of medroxyprogesterone acetate) once a day orally for 12 months, and we measured serum HGF levels and blood pressure before and 12 months after the start of HRT. RESULTS: The baseline serum HGF level was significantly higher in hypertensive PMW than in normotensive PMW. HRT significantly decreased the serum HGF level in hypertensive subjects, from 2.85 +/- 0.64 pmol/l to 2.49 +/- 0.65 pmol/l (P < 0.001), but not in normotensive subjects. HRT did not change blood pressure in either group. CONCLUSIONS: Serum HGF level before the start of HRT was higher in the hypertensive PMW than in the normotensive PMW. Furthermore, HRT decreases serum HGF without decreasing blood pressure in hypertensive PMW. The HRT-induced decrease in serum HGF was greater in hypertensive PMW than in normotensive PMW, and the decrease was independent of blood pressure changes.
Authors:
Kenichi Tamama; Hiroyuki Sumino; Shuichi Ichikawa; Tsugiyasu Kanda; Nobuo Kotajima; Yukihito Fukumura; Masahiko Kurabayashi; Masami Murakami
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  21     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-02     Completed Date:  2004-02-11     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  1151-6     Citation Subset:  IM    
Affiliation:
The Department of Laboratory Medicine, Gunma University School of Medicine, Maebashi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antihypertensive Agents / administration & dosage
Blood Pressure / drug effects*
Estrogen Replacement Therapy*
Estrogens / administration & dosage
Female
Hepatocyte Growth Factor / blood*
Humans
Hypertension / blood*,  drug therapy
Medroxyprogesterone Acetate / administration & dosage
Middle Aged
Prospective Studies
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Estrogens; 67256-21-7/Hepatocyte Growth Factor; 71-58-9/Medroxyprogesterone Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Progesterone does not influence vascular function in postmenopausal women.
Next Document:  Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization.